Preventing PML,
One patient at a time.
The PML Foundation is dedicated to protecting patients from this terrible and often fatal disease.
Red arrows shows lesion growing over time
(A > G)
Image from Anadani N, et al. 2020
FDA: PML is Fatal, No Cure or Treatment
Progressive Multifocal Leukoencephalopathy (PML) is a rare, often fatal viral disease of the central nervous system that affects patients with immunosuppressive conditions and those treated with immunomodulatory agents.
No products are approved for the treatment of PML and no therapeutic development pathway is established for PML
(natalizumab)
(ofatumumab)
(belatacept)
(rituximab)
(brentuximab vedotin)
(mycophenolate mofetil)
(obinutuzumab)
(tacrolimus)
(fingolimod)
(ofatumumab)
(alemtuzumab)
(cladribine)
(siponimod)
(ocrelizumab)
(dimethyl fumarate)
(diroximel fumarate)
(monomethyl fumarate)
(ponesimod)
(ozanimod)
(acalabrutinib)
(ibrutinib)
(axicabtagene ciloleucel)
(carfilzomib)
(polatuzumab)
(lenalidomide)
(thalidomide)
(ivosidenib)
(bortezomib)
(ruxolitinib)
(pomalidomide)
(tafasitamab-cxix)
(alemtuzumab)
(belimumab)
(vedolizumab)
(Inebilizumab)
(ruxolitinib)
(sirolimus)
(cyclosporine)
